INTRODUCTION
Despite recent improvements in therapy, lung cancer remains the leading cause of cancer-related death in the United States, 1 and stage IV lung cancer remains incurable for the vast majority of patients. As second-line treatments, erlotinib and docetaxel have produced modest benefits for unselected non-small cell lung cancer (NSCLC) populations in comparison with treatment with best supportive care. 2, 3 Subsequent clinical studies have focused on 1) improving the efficacy of these treatments by developing combination regimens and 2) identifying predictive biomarkers so that patient subgroups with sensitive tumors can be targeted.
Since the demonstration of improved survival with the addition of bevacizumab to first-line chemotherapy, 4 the addition of angiogenesis inhibitors to first-and second-line NSCLC regimens has been extensively evaluated. [5] [6] [7] [8] [9] [10] [11] Although the results have not been entirely consistent, most studies have demonstrated improved progression-free survival (PFS) and objective response rates with the addition of an angiogenesis inhibitor; some studies have also shown a modest improvement in overall survival (OS). 4, 8, 11 Simultaneous inhibition of the angiogenesis and epidermal growth factor receptor (EGFR) pathways has also been of clinical interest. Preclinical data suggesting the advantages of dual-pathway inhibition include 1) downregulation of vascular endothelial growth factor (VEGF) by EGFR inhibitors, 2) rises in VEGF levels in tumors with acquired resistance to EGFR tyrosine kinase inhibitors, and 3) activity of dual VEGF/EGFR inhibition in xenograft models resistant to EGFR tyrosine kinase inhibitors. 12, 13 Several clinical studies have shown improved activity (increased response rates and prolonged PFS) with combined VEGF and EGFR inhibition in comparison with EGFR or angiogenesis inhibition alone, although OS has not been prolonged. [5] [6] [7] 14 In this randomized, placebo-controlled phase 2 study, we evaluated the efficacy of adding pazopanib (an inhibitor of vascular endothelial growth factor receptor [VEGFR] and other tyrosine kinases) to erlotinib in the second-or third-line treatment of patients with advanced NSCLC. PFS was the primary endpoint; secondary endpoints included overall response rates, survival, and safety. In addition, the predictive value of serum proteomic testing with the VeriStrat assay (Biodesix, Boulder, Colorado) 15 was evaluated. The VeriStrat assay has previously demonstrated the ability to predict patients with favorable outcomes after treatment with erlotinib, 16 but it has not been evaluated with erlotinib-containing combination regimens.
MATERIALS AND METHODS
This randomized, placebo-controlled phase 2 trial was initiated in February 2010 and was performed at 7 participating sites: Tennessee Oncology Nashville, PLLC (Nashville, Tennessee), Chattanooga Oncology Hematology Associates (Chattanooga, Tennessee), South Carolina Oncology Associates (Columbia, South Carolina), Florida Cancer Specialists (Ft. Myers, Florida), Oncology Hematology Care (Cincinnati, Ohio), the Virginia Cancer Institute (Richmond, Virginia), and Suburban Hematology-Oncology Associates (Lawrenceville, Georgia). The study was conducted in accordance with the Declaration of Helsinki 17 and was approved by the institutional review board of each participating site before enrollment was commenced. All patients provided written informed consent.
Eligibility
To be eligible for this study, adult patients were required to have histologically confirmed stage IV NSCLC (squamous carcinoma, adenocarcinoma, or large cell carcinoma). All patients were required to have received either 1 or 2 previous chemotherapy regimens for advanced NSCLC. Previous radiation therapy was allowed, but definitive thoracic irradiation was required to have been completed at least 28 days before the study treatment was started. Additional eligibility criteria included the following: measurable disease (Response Evaluation Criteria in Solid Tumors, version 1.1); an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; adequate hematologic, hepatic, and renal function (absolute neutrophil count > 1500/mm 3 , platelet count >100,000/mm 3 , hemoglobin level > 9 g/dL, total bilirubin level 1.5 3 upper limit of normal, aspartate aminotransferase and alanine aminotransferase levels 2.5 3 upper limit of normal, serum creatinine level < 1.5 mg/ dL or calculated creatinine clearance 45 mL/min, and urine protein by dipstick < 21); and a willingness to provide serum and archived tumor biopsy samples for correlative testing.
Patients were excluded from this study if they had mixed-histology tumors containing elements of small cell carcinoma. Patients with squamous carcinoma involving the trachea or mainstem bronchi were excluded. Prior treatment with EGFR inhibitors or VEGFR inhibitors was not allowed (prior treatment with bevacizumab was allowed). Additional exclusion criteria were as follows: significant cardiovascular events within 6 months, central nervous system metastases (except if they were previously treated, were asymptomatic, and required no steroids), uncontrolled hypertension, a QTc interval > 480 milliseconds, concurrent use of drugs known to prolong QTc intervals or strongly induce/inhibit cytochrome P450 3A4, significant bleeding within 6 weeks of treatment, significant gastrointestinal abnormalities (including active peptic ulcer disease, inflammatory bowel disease, an abdominal fistula/perforation, and malabsorption), evidence of other active cancer, and pregnancy or breastfeeding.
Pretreatment Evaluation
Before the initiation of treatment, all patients underwent a complete history and physical examination, an evaluation of their ECOG performance status, a review of concomitant medications, a review of their cigarette smoking history, complete blood counts, a chemistry profile, a serum amylase test, a prothrombin time test, and thyroid function tests (thyroxine and thyroid-stimulating hormone). The baseline tumor status was assessed with computed tomography of the chest and abdomen, computed tomography or magnetic resonance imaging scan of the brain, and positron emission tomography or bone scanning.
Treatment
Before randomization, patients were stratified according to their histology (squamous vs nonsquamous) and prior exposure to bevacizumab (yes or no). Patients were then randomized (2:1) to receive either erlotinib (150 mg orally daily) plus pazopanib (600 mg orally daily; arm 1) or erlotinib plus daily oral placebo (arm 2). No standard premedications were required with either treatment regimen. During treatment, medications to ameliorate side Original Article effects (eg, antiemetics and antidiarrheals) were used at the discretion of the treating physician.
During treatment, patients were seen by their treating physician once every 4 weeks, and they were first evaluated for a response (repeat computed tomography scans) after 8 weeks of treatment. Responses were categorized with the Response Evaluation Criteria in Solid Tumors (version 1.1). 18 Patients who had a complete response, a partial response, or stable disease continued treatment until disease progression or unacceptable toxicity occurred; repeat disease assessments were performed every 8 weeks.
Dose Modifications
Toxicities were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0), and dose modifications were based on the organ system exhibiting the worst toxicity. Complete dose modifications were outlined in the study protocol. Specific dose modifications and management guidelines were included for hematologic toxicity and also for nonhematologic toxicities expected with erlotinib (diarrhea, nausea/vomiting, skin toxicity, and interstitial lung disease) and pazopanib (hypertension, skin toxicity, hepatic toxicity, proteinuria, hemorrhage/bleeding, venous thrombosis, and QTc prolongation).
A maximum of 1 dose reduction of erlotinib and pazopanib/placebo was allowed (the reduced doses were 100 mg daily for erlotinib and 400 mg daily for pazopanib/placebo). Patients in arm 1 who required a toxicityrelated treatment delay > 4 weeks or who had a recurrent severe toxicity after the maximum dose reduction were required to discontinue treatment with the offending agent. Patients who discontinued a component of the treatment because of toxicity were allowed to continue using the remaining agent if they were judged to be benefiting from the therapy.
Correlative Studies
During patient enrollment in this trial, the study was amended to enable the collection of serum for proteomic testing with the VeriStrat assay. 15 The purpose of this correlative study was to evaluate the role of the assay in predicting the outcome of treatment with the 2 erlotinibbased study treatment regimens. After the study amendment, patients gave consent to provide pretreatment serum specimens so that the VeriStrat assay could be performed.
The VeriStrat assay has previously been shown to identify patients with advanced NSCLC who are likely to have a good survival outcome after second-or third-line treatment with erlotinib. 16 In this trial, samples were collected and sent to the Clinical Laboratory Improvement Amendments-accredited Biodesix laboratory for the performance of the VeriStrat assay. On the basis of the assay results, patients were separated into good and poor categories according to the predicted outcome with erlotinib therapy.
Statistical Considerations
An assessment of treatment efficacy was the primary objective of this trial; PFS was the primary endpoint. Treatment with single-agent erlotinib was expected to produce a median PFS of 2.2 months for patients with previously treated advanced NSCLC. 3 To improve the PFS by 50% (ie, from 2.2 to 3.3 months) with 80% power at the 1-sided a level of 5%, the targeted enrollment of this study was 197 patients (under the assumption of a 10% dropout rate).
All eligible patients who were randomized were included in the efficacy analyses. PFS and OS were analyzed with Kaplan-Meier methods. 19 The median PFS and OS for the 2 treatment arms were compared with the log-rank test; they were stratified for histology and prior bevacizumab use. Patients who discontinued treatment for reasons other than tumor progression or death were censored for PFS on the date on which the treatment was discontinued. Patients who were lost to follow-up were censored on the date of the last imaging assessment. All patients who received at least 1 dose of treatment were included in the safety analysis. The worst toxicity grades per patient were tabulated for each adverse event or laboratory abnormality. The frequency of toxicities was enumerated for each treatment arm.
For the subset of patients for whom the VeriStrat assay was performed, the results were retrospectively correlated with the PFS and OS of the entire patient population and each treatment arm. Prognostic factors were evaluated with univariate chi-square testing, and they included sex, race, tumor histology, prior bevacizumab treatment, smoking history, performance status, study treatment received, and VeriStrat category.
RESULTS

Patient Characteristics and Treatment
Between February 2010 and February 2011, 202 patients were randomized (arm 1, 135; arm 2, 67). Two patients withdrew from the study before receiving treatment, and 10 patients were found to be ineligible and were withdrawn. Nine of these 10 patients were ineligible because they had relapsed after combined-modality therapy for stage IIIA lung cancer but had not received any previous treatment for metastatic disease. Therefore, 190 patients received treatment per the study protocol, as summarized in Figure 1 .
At the time of this writing, all 190 patients had discontinued the study treatment. Disease progression (115 patients) was the most common reason for treatment discontinuation. Thirty patients (16%) discontinued treatment because of toxicity (arm 1, 26; arm 2, 4), as detailed in Figure 1 .
Patient and disease characteristics are summarized in Table 1 . Most characteristics were balanced between treatment arms; however, more patients receiving erlotinib plus placebo had a poor performance status (25% vs 9%). An assessment of the EGFR mutation status was performed for only a few patients in this study; the comparability of the treatment groups in relation to this variable is, therefore, unknown.
Patients in both treatment arms received a median of 2 treatment cycles (range for arm 1, 1-22 cycles; range for arm 2, 1-8 cycles). In arm 1, 35 patients (28%) required dose reductions (pazopanib only, 4 patients; erlotinib only, 3 patients; both drugs, 28 patients). In 6 patients, discontinuation of 1 drug was required (pazopanib, 4 patients; erlotinib, 2 patients), but treatment with the other agent was continued. In treatment arm 2, erlotinib was dose-reduced in 12% because of toxicity. 
Efficacy
The efficacy of each treatment regimen is summarized in Table 2 . A total of 149 patients were evaluated for their responses. Forty-three patients (arm 1, 34 patients; arm 2, 9 patients) discontinued study treatment before the first re-evaluation for the following reasons: rapid clinical decline (4 patients) or death (9 patients) related primarily to the underlying lung cancer, treatment-related toxicity (14 patients), patient/physician decision (additional details not captured; 10 patients), intercurrent illness (5 patients), and noncompliance (1 patient).
The median PFS was 2.6 months (95% confidence interval [CI], 1.9-3.2 months) for patients receiving erlotinib plus pazopanib and 1.8 months (95% CI, 1.7-2.0 months) for patients receiving erlotinib plus placebo (hazard ratio [HR], 0.58; P 5 .001). The PFS curves for the 2 treatment arms are shown in Figure 2 .
The median OS was 6.9 months (95% CI, 4.9-8.5 months) for patients receiving erlotinib plus pazopanib and 7.0 months (95% CI, 5.0-9.5 months) for patients receiving erlotinib plus placebo (HR, 0.99; P 5 .94). The 1-year survival probabilities were 28% and 29%, respectively. The OS curves for each group are shown in Figure 3 .
Objective response rates were low in both treatment arms. Thirteen patients (10%) receiving erlotinib plus pazopanib had partial responses, whereas 3 of those receiving erlotinib plus placebo (5%) did (Table 2) .
Toxicity
Serious toxicities (grade 3 or 4) occurring at frequencies of 5% or greater in either treatment arm are detailed in Table  3 . The spectrum of toxicities is consistent with the toxicities previously reported with these agents. The combination of erlotinib and pazopanib produced more frequent and severe toxicities: 25% of the patients on this regimen had at least 1 serious adverse event, whereas 5% of those receiving erlotinib plus placebo did. Toxicity led to treatment discontinuation in 26 patients (21%) receiving pazopanib plus erlotinib but in only 4 patients (6%) receiving erlotinib plus placebo. Patients who had received 2 prior treatment regimens or had a poor performance status at study entry had higher treatment discontinuation rates. The most common toxicities associated with treatment discontinuation were skin toxicities (9 patients), hepatotoxicities (6 patients), and nausea/vomiting/diarrhea (4 patients); see Figure 1 for a complete listing.
Correlation of Survival With the VeriStrat Assay Prediction
Pretreatment samples from 93 patients were sent for the VeriStrat assay, and the assay was successfully performed for 91 patients. Three of these patients were among the group of 10 patients subsequently found to be ineligible for the trial, and they were excluded. The 88 patients who had VeriStrat assays performed were similar in patient characteristics (age, sex, ECOG performance status, histology, smoking history, and previous treatment) in comparison with the overall study population. The VeriStrat scores were good for 63 patients (72%) and poor for 25 patients (28%). A good VeriStrat score was correlated with a good ECOG performance status but was not associated with histology, smoking history, or previous bevacizumab treatment.
In the patient group tested with the VeriStrat assay (n 5 88), patients with good scores had better PFS and OS than patients with poor scores did (Figs. 4A and 5A ). The predictive value of the VeriStrat scores were also evaluated according to the treatment regimen received. Patients who had a good VeriStrat score and received erlotinib plus pazopanib had better PFS than patients receiving erlotinib plus placebo did (median, 3.6 vs 1.8 months; HR, 0.47; Fig. 4B ). Patients who had poor VeriStrat scores had similar PFS whether they received erlotinib plus pazopanib or erlotinib plus placebo (median, 1.8 vs 1.7 months; HR, 0.87; Fig. 4C ). OS was similar, regardless of the treatment received, for patients with good VeriStrat scores (erlotinib plus pazopanib, 8.2 months; erlotinib plus placebo, 8.6 months; HR, 1.02; Fig. 5B ). Patients with poor VeriStrat scores who received pazopanib plus erlotinib appeared to have shorter survival than those receiving erlotinib alone (2.8 vs 7.5 months; P 5 .11; Fig. 5C) ; however, the interpretation of this finding is difficult because of the small patient numbers in these groups.
A univariate analysis of potential prognostic factors showed that the VeriStrat score (good vs poor) was the best predictor of PFS (P 5 .0009) and OS (P 5 .0004; Table 4 ). Treatment with erlotinib plus pazopanib was associated with improved PFS (P 5 .001) but not OS. A good performance status at study entry was associated with longer OS (P 5 .006). Other variables examined (sex, race, histology, smoking history, and prior bevacizumab treatment) were not associated with significant survival differences in this study.
DISCUSSION
Erlotinib has modest activity in the treatment of unselected patients with metastatic NSCLC. 3 In attempts to improve the efficacy of erlotinib-based treatment, various combination regimens, including combinations of erlotinib with various angiogenesis inhibitors, have been evaluated. Preclinical data suggested that the simultaneous inhibition of angiogenesis and the EGFR pathway may have additive or synergistic effects. 12, 13, [20] [21] [22] In the second-line treatment of advanced NSCLC, the combination of bevacizumab and erlotinib improved PFS in comparison with erlotinib alone.
14 Pazopanib, a multitargeted tyrosine kinase inhibitor, has produced single-agent responses in patients with refractory NSCLC 23 and has potential advantages in comparison with bevacizumab through the inhibition of potentially relevant targets in addition to the VEGF receptor. A previous phase 1 trial had demonstrated the feasibility of administering the erlotinib and pazopanib combination, although the maximum tolerated dose of pazopanib (as used in this study) was 75% of the recommended single-agent dose. 24 This trial was, therefore, designed for the primary purpose of evaluating the efficacy of the erlotinib and pazopanib combination in the second-and third-line treatment of patients with metastatic NSCLC.
In this trial, treatment with erlotinib plus pazopanib resulted in a prolongation of PFS in comparison with erlotinib plus placebo (median PFS, 2.6 vs 1.8 months; (21) 4 (6) 30 (16) HR, 0.58). However, neither regimen had impressive efficacy: both produced short median PFS times and low response rates. The addition of pazopanib had no effect on OS while substantially increasing toxicity (26 patients discontinued treatment because of toxicity with erlotinib plus pazopanib, whereas 4 patients receiving erlotinib alone did). The results of this trial (modest prolongation of PFS, no effect on OS, and increased toxicity) are similar to the results of other trials evaluating the combination of angiogenesis inhibitors and EGFR inhibitors. [5] [6] [7] 14 A secondary goal of this trial was to evaluate the clinical utility of the VeriStrat assay, a serum proteomic test previously demonstrated to be useful in predicting those patients with NSCLC likely to benefit from erlotinib therapy. 16 In this study, our goals were 1) to confirm the predictive value of the VeriStrat assay in patients receiving erlotinib and 2) to evaluate the predictive benefits of the test in patients receiving the erlotinib and pazopanib combination regimen. Since this portion of the study was added as an amendment, only a subset of patients were studied. However, among the 88 patients who had VeriStrat assays performed, patients with good scores had better PFS and OS than patients with poor scores, and this confirmed the results of previous studies. 15, 16, 25 When VeriStrat scores in the 2 treatment groups were evaluated separately, good VeriStrat scores predicted longer PFS (HR, 0.47) but not OS (HR, 1.02) for patients receiving erlotinib plus pazopanib. Patients with poor VeriStrat scores had similarly poor treatment results with erlotinib plus pazopanib and erlotinib plus placebo (median PFS, 1.8 vs 1.7 months).
Since this study was designed, the role of EGFR inhibitors in the treatment of NSCLC has evolved. In patients with EGFR-activating mutations, these agents are more active and less toxic than standard combination chemotherapy, and they are now the first-line treatment of choice. However, for the remaining patients with NSCLC, drugs more efficacious than the EGFR inhibitors are now available, and the use of EGFR inhibitors in unselected patient populations has declined. With this declining use, the clinical relevance of the VeriStrat test is also questionable because its predictive value is specific to patients receiving EGFR inhibitors. With current therapeutic options, treatment with an EGFR inhibitor is usually not considered before fourth-line treatment; perhaps a good VeriStrat score could assist in selecting patients in this refractory group most likely to benefit from therapy.
The role of angiogenesis inhibitors in the treatment of NSCLC has also evolved. After multiple clinical trials involving various angiogenesis inhibitors and multiple combinations, several generalizations can be made. First, all angiogenesis inhibitors evaluated to date have limited single-agent activity. Second, in most studies, the addition of an angiogenesis inhibitor has produced a modest prolongation of the median PFS, but a prolongation of OS has not been achieved. Finally, the toxicity of oral VEGFR tyrosine kinase inhibitors is substantial, and the development of tolerable combinations containing these agents has been difficult. Therefore, the addition of an angiogenesis inhibitor to a treatment regimen for an unselected population of patients with advanced NSCLC seems unlikely to produce a meaningful improvement in efficacy.
Efforts to identify molecular markers predictive of a response to angiogenesis inhibition have so far been generally unsuccessful. However, recent studies have suggested that the addition of angiogenesis inhibition to EGFR inhibition may have specific benefits for patients with EGFR-mutated NSCLC. 14, 26 The median PFS was substantially prolonged for patients receiving erlotinib plus bevacizumab as a first-line treatment versus erlotinib alone (19 vs 9.7 months; HR, 0.54). 25 The further development of regimens combining angiogenesis and EGFR inhibitors may be appropriate in this selected subset of NSCLC patients.
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